Table 2.
Pharmacotherapy/Device Use
| All Patients With LVEF ≤35% by NYHA Class | All Patients by NYHA Class | |||||
|---|---|---|---|---|---|---|
| NYHA II + LVEF ≤35%, n = 57 | NYHA III/IV + LVEF ≤35%, n = 87 | P Value | NYHA II, n = 202 | NYHA III/IV, n = 162 | P Value | |
| % | % | % | % | |||
| ACEIs | 77.2 | 69.0 | 0.2811 | 68.8 | 64.8 | 0.4201 |
| ARBs | 21.1 | 27.6 | 0.3759 | 26.7 | 28.4 | 0.7240 |
| ACEIs and/or ARBs | 94.7 | 92.0 | 0.5206 | 93.1 | 88.9 | 0.1616 |
| β‐Blockers | 93.0 | 92.0 | 0.8203 | 94.1 | 85.2 | 0.0048 |
| Diuretics | 80.7 | 88.5 | 0.1944 | 81.2 | 90.7 | 0.0102 |
| MRAs | 54.4 | 64.4 | 0.2310 | 43.6 | 55.6 | 0.0229 |
| Ivabradine | 0.0 | 10.3 | 0.0524 | 3.9 | 11.0 | 0.0362 |
| Anticoagulants | 38.6 | 51.7 | 0.1225 | 39.6 | 46.9 | 0.1614 |
| CRT | 12.5 | 14.9 | 0.7125 | 9.0 | 8.6 | 0.884 |
| ICD | 0.0 | 8.3 | 0.5035 | 0.0 | 7.7 | 0.2398 |
| ACEI/ARBs, β‐blockers, diuretics, and MRAs combined | 42.1 | 52.9 | 0.2061 | 34.2 | 38.9 | 0.3508 |
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter‐defibrillator; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.